Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
NCT03630120 · H. Lee Moffitt Cancer Center and Research Institute · PHASE2 · terminated · last registry update 2021-07-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, H. Lee Moffitt Cancer Center and Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-06-27Phase 3 first posted: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2022-04-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Cabozantinib (NCT03141177)
- 2022-03-31Phase 3 first posted: AstraZeneca, Tremelimumab + Durvalumab (NCT05301842)
- 2022-01-26Phase 3 first posted: Cogent Biosciences, Inc., CGT9486 + CGT9486 (NCT05208047)
- 2021-09-28Phase 3 first posted: Pfizer, Avelumab + Lorlatanib (NCT05059522)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-08-03Phase 3 first posted: AVEO Pharmaceuticals, Inc., Tivozanib + Nivolumab (NCT04987203)
- 2021-07-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Lenvatinib (NCT04949256)
- 2021-03-12Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cediranib Maleate (NCT02446600)
- 2021-02-25Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Lenvatinib (NCT04770896)
- 2021-02-03Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT04736706)
- 2021-01-25Phase 3 first posted: Shanghai Junshi Bioscience Co., Ltd., Toripalimab combined with Bevacizumab + Sorafenib (NCT04723004)
- 2020-12-16Results posted on the registry: SillaJen, Inc., Pexastimogene Devacirepvec (Pexa Vec) + Sorafenib (NCT02562755)
- 2020-12-10Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Lenvatinib (NCT04662710)
- 2020-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Belzutifan + Lenvatinib (NCT04586231)
- 2020-10-09Results posted on the registry: National Cancer Institute (NCI), Doxorubicin + Doxorubicin Hydrochloride (NCT02180867)
- 2020-08-21Phase 3 first posted: Shanghai Junshi Bioscience Co., Ltd., Toripalimab combined with Lenvatinib + Placebo combined with Lenvatinib (NCT04523493)
- 2020-08-12Phase 3 first posted: SWOG Cancer Research Network, Active Comparator (NCT04510597)
- 2020-07-22Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Olaparib (NCT01116648)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision